Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis

Recent preclinical and clinical studies lend support to the notion that B-cell depletion is a promising therapeutic target in patients with diffuse cutaneous systemic sclerosis. A recent open-label trial provides further evidence showing marked effects of rituximab treatment on skin thickening, functional ability, and disease activity in conjunction with effects on lesional and circulating B ce...

Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.

Rituximab in early systemic sclerosis

OBJECTIVES (1) Hypothesis testing of the potency of rituximab (RTX) in preventing fibrotic complications and (2) assessing acceptability and feasibility of RTX in early systemic sclerosis (SSc). METHODS A small, 24-month, randomised, double-blind, placebo-controlled, single-centre trial in patients with SSc diagnosed <2 years was conducted. Patients received RTX or placebo infusions at t=0, t...

Erythema nodosum :what should we consider about it?

Fluoride varnishes: should we be using them?

Fluoride varnishes are fast becoming the standard of care as topical fluoride treatments. Fluoride varnishes still await approval from the FDA for use as caries preventive agents. In the meantime, their use for such purposes is considered "off-label." This article highlights the efficacy of fluoride varnishes as caries preventive agents and introduces some of the commercially available fluoride...